Paweł Moćko
Jagiellonian University Medical College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paweł Moćko.
Pharmacological Reports | 2016
Paweł Moćko; Paweł Kawalec; Andrzej Pilc
BACKGROUND Crohn disease (CD) is an inflammatory bowel disease which occurs especially in developed countries of Western Europe and North America. The aim of the study was to compare the safety profile of biologic drugs in patients with CD. METHODOLOGY A systematic literature search was performed using PubMed, Embase, and CENTRAL databases, until April 27, 2016. We included randomized controlled trials (RCTs) that compared the safety of biologic drugs (infliximab, adalimumab, vedolizumab, certolizumab pegol, and ustekinumab) with one another or with placebo in patients with CD. The network meta-analysis (NMA) was conducted for an induction phase (6-10 weeks) and maintenance phase (52-56 weeks) with a Bayesian hierarchical random effects model in the ADDIS® software. The PROSPERO registration number was CRD42016032606. RESULTS Ten RCTs were included in the systematic review with NMA. In the case of the induction phase, the NMA could be conducted for the assessment of the relative safety profile of adalimumab, vedolizumab, certolizumab pegol, and ustekinumab, and in the case of the maintenance phase-of infliximab, adalimumab, and vedolizumab. There were no significant differences in the rate of adverse events in patients treated with biologics. Statistical analysis revealed that vedolizumab had the greatest probability of being the safest treatment in most endpoints in the induction phase and adalimumab-in the maintenance phase. CONCLUSIONS No significant differences between the biologics in the relative safety profile analysis were observed. Further studies are needed to confirm our findings, including head-to-head comparisons between the analyzed biologics.
Expert Review of Pharmacoeconomics & Outcomes Research | 2015
Ewa Stawowczyk; Krzysztof Piotr Malinowski; Paweł Kawalec; Paweł Moćko
The aim of this systematic review is to collect and summarize all current data on the indirect costs related to absenteeism and presenteeism associated with multiple sclerosis. Searches were conducted using Medline, Embase and Centre for Reviews and Dissemination databases. All collected costs were recalculated to average annual cost per patient, expressed in 2014 prices US
Archives of Medical Science | 2016
Paweł Moćko; Paweł Kawalec; Beata Smela-Lipińska; Andrzej Pilc
using the consumer price index and purchasing power parity (scenario 1) and expressed as proportion of specific gross domestic product in current local currency unit to adjust for country’s development (scenario 2). Identified studies were then analyzed in order to assess their possible inclusion in the meta-analysis. The authors identified 63 records, of which 23 were eligible for meta-analysis. Overall indirect cost per patient calculated in scenario 1 was as high as US
Journal of Comparative Effectiveness Research | 2017
Paweł Kawalec; Paweł Moćko; Iwona Malinowska-Lipień; Tomasz Brzostek
20,167 with US
Pharmacotherapy | 2016
Paweł Kawalec; Paweł Moćko; Andrzej Pilc; Maria Radziwon-Zalewska; Iwona Malinowska-Lipień
22,197 in Europe, US
Expert Review of Pharmacoeconomics & Outcomes Research | 2016
Krzysztof Piotr Malinowski; Paweł Kawalec; Paweł Moćko
17,382 in North America and US
Zdrowie Publiczne i Zarządzanie | 2016
Paweł Moćko; Paweł Kawalec; Krzysztof Piotr Malinowski
153 in Asia. Overall indirect cost per patient calculated in scenario 2 was equal to US
Journal of Comparative Effectiveness Research | 2018
Paweł Kawalec; Paweł Moćko
16,939, with US
Medycyna Rodzinna | 2016
Paweł Moćko; Paweł Kawalec; Katarzyna Antoniewicz; Andrzej Pilc
19,612 in Europe, US
Medycyna Rodzinna | 2016
Paweł Moćko; Paweł Kawalec; Andrzej Pilc
11,592 in North America and US